雾化吸入布地奈德联合溴己新治疗小儿重症肺炎的临床研究  

Clinical trial of aerosol inhalation budesonide combined with bromhexine in the treatment of severe pneumonia in children

作　　者：唐云丽[1] 康丽 邹登[1] 邓发文[1] TANG Yun-li;KANG Li;ZOU Deng;DENG Fa-wen(Department of Neonatology,The Fourth Hospital of Changsha,Changsha 410000,Hunan Province,China)

机构地区：[1]长沙市第四医院新生儿科,湖南长沙410000

出　　处：《中国临床药理学杂志》2023年第2期160-163,共4页The Chinese Journal of Clinical Pharmacology

摘　　要：目的 研究雾化吸入布地奈德联合溴己新治疗小儿重症肺炎的临床疗效及对降钙素原(PCT)水平变化的影响。方法 将80例重症肺炎患儿随机分为试验组41例和对照组39例。对照组给予布地奈德,每次1 mg,bid,雾化吸入;试验组给予布地奈德每次1 mg,bid,雾化吸入,盐酸溴己新葡萄糖注射液每次2~4 mg,qd,静脉滴注。2组患儿均用药1周。比较2组治疗前后的临床疗效、炎症因子水平、免疫功能、PCT水平及药物不良反应发生情况。结果 治疗后,试验组总有效率(92.68%)显著高于对照组(71.79%),差异有统计学意义(P<0.05)。试验组发热、咳嗽、呼吸困难、肺啰音消失时间分别为(2.00±0.77),(3.85±1.48),(1.54±0.50)及(5.24±1.28)d,对照组分别为(2.49±0.51),(5.51±1.41),(2.08±0.84)及(6.36±2.01)d,差异均有统计学意义(均P<0.05)。试验组和对照组的免疫球蛋白A(IgA)分别为(0.55±0.08),(0.77±0.21)g·L^(-1);免疫球蛋白M(IgM)分别为(0.87±0.25),(1.44±0.36)g·L^(-1);PCT分别为(0.41±0.11),(0.92±0.26)ng·mL^(-1);C反应蛋白(CRP)分别为(13.11±3.38),(22.69±6.50)mg·L^(-1);白细胞介素-6(IL-6)水平分别为(11.47±3.60),(17.85±6.60)pg·mL^(-1);免疫球蛋白G(IgG)分别为(10.83±1.24),(9.83±2.26)g·L^(-1),差异均有统计学意义(均P<0.05)。试验组药物不良反应发生率为14.63%,对照组为30.77%,差异无统计学意义(P>0.05)。结论 雾化吸入布地奈德联合溴己新治疗小儿重症肺炎的临床疗效更好,并且能加快缓解临床症状,有助于患儿恢复,能有效降低PCT含量,降低炎症因子水平,延缓疾病发展。Objective To study the clinical efficacy of aerosol inhalation budesonide combined with bromhexine in the treatment of severe pneumonia in children and its effect on the level of procalcitonin(PCT).Methods A total of 80 children with severe pneumonia were randomly divided into treatment group(n=41) and control group(n=39). Control group was given budesonide, 1 mg each time, bid, aerosol inhalation. Treatment group was given bromhexine hydrochloride glucose injection 2-4 mg each time, qd, intravenous drip on the basis of control group. Both groups were treated for 1 week. The clinical efficacy, inflammatory factor levels, immune function, PCT levels and adverse drug reactions were observed and compared between the two groups.Results After treatment,the total effective rate of treatment group( 92. 68%) was significantly higher than that of control group( 71. 79%,P < 0. 05). The disappearance time of clinical symptoms of fever,cough,dyspnea and pulmonary rales in treatment group were( 2. 00 ± 0. 77),( 3. 85 ± 1. 48),( 1. 54 ± 0. 50) and( 5. 24 ± 1. 28) d,respectively,which in control group were( 2. 49 ± 0. 51),( 5. 51 ± 1. 41),( 2. 08 ± 0. 84) and( 6. 36 ± 2. 01) d,and the difference were statistically significant( all P < 0. 05). The immunoglobulin A( IgA) of treatment group and control group were( 0. 55 ± 0. 08) and( 0. 77 ± 0. 21) g·L^(-1);the immunoglobulin M( IgM) were( 0. 87 ± 0. 25)and( 1. 44 ± 0. 36) g·L^(-1);PCT were( 0. 41 ± 0. 11),( 0. 92 ± 0. 26) ng·m L-1;C-reactive protein( CRP) were( 13. 11 ± 3. 38),( 22. 69 ± 6. 50) mg·L^(-1);interleukin-6( IL-6) levels were( 11. 47 ± 3. 60),( 17. 85 ± 6. 60)pg· m L-1;the immunoglobulin G( IgG) were( 10. 83 ± 1. 24),( 9. 83 ± 2. 26) g·L^(-1);the difference were statistically significant( all P < 0. 05). The incidence of adverse drug reactions in treatment group was 14. 63%,which in control group was 30. 77% and the difference was not statistically significant( P > 0. 05). Conclusion The clinical efficacy of aerosol inhalation budesonide combi

关 键 词：布地奈德 雾化吸入 溴己新 重症肺炎 降钙素原 

分 类 号：R974[医药卫生—药品]